Who Shouldn’t Take GLP-1? Considerations Most People Miss

Roughly 12.4% of U.S. adults reported using a GLP-1 medication for weight loss by late 2025, according to KFF survey data. That’s more than double the figure from earlier that same year. The demand is real, and so is the hype.

But GLP-1 medications aren’t a fit for everyone. If you have a personal or family history of certain thyroid cancers, a record of pancreatitis, severe digestive conditions, or are pregnant, these drugs may do more harm than good. Some people can’t take them at all. Others need close monitoring before their provider writes the first prescription.

GLP-1 medications are prescription drugs that mimic a natural gut hormone to lower blood sugar, slow digestion, and reduce appetite. They’re approved for Type 2 diabetes and weight management, but certain health conditions, allergies, and life stages make them unsafe or risky for specific patients. Your medical history determines whether you’re a candidate.

This article won’t cover what to eat while on a GLP-1 or how to manage side effects once you’ve started. That’s a different conversation. This is about whether you should start at all.

How GLP-1 Medications Work

GLP-1 stands for glucagon-like peptide-1. Your gut produces this hormone naturally after meals. It tells your pancreas to release insulin, signals your liver to slow down sugar production, and sends fullness cues to your brain.

Medications like semaglutide (sold as Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound) are synthetic versions of that hormone. Tirzepatide also mimics a second hormone called GIP, which is why some clinical trials show it producing greater weight loss than semaglutide alone.

These drugs slow stomach emptying. That’s the mechanism behind reduced appetite, but it’s also behind many of the GI side effects people report. Patients at clinics offering medical weight loss programs often tolerate the adjustment period well with proper guidance, but not everyone does.

The ADA’s 2025 Standards of Care now recommend GLP-1 receptor agonists for glycemic control, weight management, and heart and kidney protection in qualifying Type 2 diabetes patients. That’s a strong endorsement, but endorsement and individual safety aren’t the same thing.

Who Should Avoid GLP-1 Medications?

Most people tolerate GLP-1 drugs without serious problems. But “most” isn’t “all,” and the contraindications are worth knowing before you ever schedule a consultation at a GLP-1 clinic in Miramar, FL. Your provider should screen for every one of these before prescribing.

Thyroid Cancer and MEN 2 Syndrome

Every FDA-approved GLP-1 carries a boxed warning (the strongest warning the FDA issues) because of thyroid C-cell tumors found in rodent studies. This risk hasn’t been confirmed in humans, but the FDA’s prescribing labels treat it seriously.

GLP-1 medications are contraindicated if you have a personal or family history of medullary thyroid cancer (MTC). They’re also off the table if you’ve been diagnosed with multiple endocrine neoplasia syndrome type 2 (MEN 2), a rare genetic condition that raises MTC risk.

If you’ve had a different type of thyroid cancer, you might still be a candidate. But many wellness users skip the family history screening entirely, and that’s a mistake I’ve seen play out. One case reported in practitioner forums involved weight loss on a GLP-1 that revealed previously undetected thyroid nodules. Get the screening done first.

Is a GLP-1 Safe After Pancreatitis?

GLP-1 drugs have been linked to acute pancreatitis, a sudden inflammation of the pancreas. People with a history of pancreatitis were excluded from the major clinical trials (SUSTAIN and PIONEER), so the safety data for this group is thin.

The picture is more mixed than most articles admit. A 2024 presentation at the Endocrine Society’s ENDO conference showed that semaglutide and tirzepatide may actually lower the risk of a repeat pancreatitis episode in certain Type 2 diabetes patients. But until larger studies confirm that, most providers err on the side of caution and avoid prescribing GLP-1s to anyone with prior pancreatitis.

If you’ve had pancreatitis before, don’t write off GLP-1s entirely. Do bring it up with your provider and ask them to weigh the newer research against your specific history.

Severe Stomach and Digestive Conditions

Because GLP-1 medications slow gastric emptying, they can worsen conditions where the stomach already empties too slowly. Gastroparesis is the big one. A 2023 JAMA study found GLP-1 users had 3.67 times the risk of gastroparesis compared to a control group on bupropion-naltrexone. The same study showed a 4.22x risk of bowel obstruction.

Those numbers matter. As of early 2026, over 3,000 lawsuits have been consolidated in federal court (MDL 3094) against Novo Nordisk and Eli Lilly. The claims center on gastroparesis, bowel obstruction, and a rare eye condition called NAION.

If you already have severe gastroparesis or a history of intestinal blockages, GLP-1 medications are not recommended. The FDA labels for both Wegovy and Zepbound say exactly that. And if you’re someone who works with a team that understands how to communicate these risks clearly, you’ll know this isn’t a gray area.

Allergic Reactions to GLP-1 Ingredients

This one sounds obvious, but the details trip people up. You shouldn’t take any GLP-1 if you’ve had a serious allergic reaction (anaphylaxis, angioedema) to its ingredients. Reactions are rare, but they happen.

The part most people miss is that ingredients vary between brands. Ozempic and liraglutide injections (Saxenda, Victoza) contain propylene glycol and a preservative that other GLP-1s don’t. So a reaction to one brand doesn’t automatically rule out every GLP-1 on the market. Your provider can cross-reference your allergy list against the specific ingredient profiles.

Are GLP-1s Safe During Pregnancy or While Nursing?

No. GLP-1 medications are not recommended during pregnancy. Animal studies show potential fetal risks, and there’s almost no human safety data. If you’re planning to conceive, your provider will likely tell you to stop the medication at least two months before trying. That’s the clearance window.

If you discover you’re pregnant while on a GLP-1, contact your provider immediately. For women with Type 2 diabetes, ADA guidelines recommend insulin as the safest pregnancy treatment.

Nursing carries similar uncertainty. The oral GLP-1 Rybelsus specifically advises against use while breastfeeding. Other brands don’t have enough data to say it’s safe, so most providers recommend stopping.

Other Conditions That Need Monitoring

Some conditions don’t automatically disqualify you, but they do require your provider to watch more closely. Conditions worth discussing include eating disorders (especially restrictive types like anorexia, where appetite suppression can be dangerous), depression and mood disorders, a history of gallstones, and diabetic retinopathy.

The eating disorder angle is underreported. GLP-1 drugs reduce “food noise,” the constant mental chatter about eating. For most people, that’s a benefit. For someone recovering from anorexia or another restrictive eating disorder, it can be a trigger. I’ve seen wellness clinics gloss over this in their marketing, and it’s a real blind spot.

One more that rarely gets airtime: if you’re scheduled for surgery, you need to stop your GLP-1 beforehand. The American Society of Anesthesiologists and the ADA’s 2025 guidance both flag aspiration risk from delayed gastric emptying during anesthesia. Hold daily GLP-1s on the day of surgery. Hold weekly injections about a week before. Skipping this step is one of the most costly mistakes I’ve come across in wellness patient care.

How Do You Know If a GLP-1 Is Right for You?

The answer is a conversation, not a checklist. But that conversation should cover specific ground. Providers reviewing patients at practices like Revive 365 Wellness will look at your full medical history, current medications, allergy list, and reproductive plans before recommending a GLP-1.

Three things to bring up on your own if your provider doesn’t ask:

1. Your complete family history, including thyroid cancer in any relative. Many providers screen for personal history but don’t dig into family.
2. Surgical plans in the next 3-6 months. If a procedure is coming up, the timing of GLP-1 initiation matters.
3. Your history with food and eating patterns. A provider who specializes in GLP-1 prescribing will want to understand your relationship with food before adding a drug that changes appetite signaling.

If GLP-1s aren’t right for you, alternatives exist. Anyone exploring whether they’re a candidate for peptide-based therapies should know that other approaches to peptide therapy for weight loss can work for patients who can’t tolerate GLP-1 drugs.

The single most important takeaway: GLP-1 medications are powerful, but power and safety aren’t the same thing. These drugs work for the right patients, and that’s exactly why demand has doubled in a single year. That doesn’t mean they work for you. Get screened properly. Ask the uncomfortable questions. And if something feels off after you start, speak up before your next dose.

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Always consult your doctor or qualified health professional before starting, stopping, or changing any medication or treatment plan. Individual results and risks vary based on your personal health history. Revive 365 Wellness does not guarantee specific outcomes and recommends working directly with your care team to determine the right approach for your needs. 

FAQs

Can I take a GLP-1 if I have a history of pancreatitis?

Most providers won’t prescribe a GLP-1 if you’ve had pancreatitis, because people with that history were excluded from the major clinical trials. But newer research is shifting the picture. A 2024 study presented at the Endocrine Society’s ENDO conference found that semaglutide and tirzepatide may actually reduce the risk of pancreatitis recurrence in certain patients with Type 2 diabetes. Bring the question to your provider with this context.

Is it safe to take GLP-1 medications during pregnancy?

No. GLP-1 medications are not recommended during pregnancy due to potential fetal risks shown in animal studies. If you’re planning to conceive, providers typically recommend stopping the medication at least two months before trying. The ADA’s 2025 guidelines list insulin as the safest option for managing Type 2 diabetes during pregnancy.

What’s the thyroid cancer risk with GLP-1 drugs?

Every GLP-1 medication carries an FDA boxed warning about thyroid C-cell tumors found in rodent studies. This risk hasn’t been confirmed in humans. But the drugs are completely off-limits if you have a personal or family history of medullary thyroid cancer or a diagnosis of MEN 2 syndrome. Other types of thyroid cancer may not be disqualifying, but your provider needs to evaluate your specific situation.

Do I need to stop my GLP-1 before surgery?

Yes. The American Society of Anesthesiologists and the ADA’s 2025 perioperative guidance both recommend holding GLP-1 medications before procedures involving anesthesia. Daily GLP-1s should be held on the day of surgery. Weekly injections should be held about one week prior. The concern is aspiration risk from delayed gastric emptying.

Are compounded GLP-1 medications safe?

The FDA issued a safety communication in February 2026 warning about quality problems with compounded GLP-1 products, including impurities, incorrect dosing, and contamination. Hundreds of adverse event reports were logged by mid-2025. FDA-approved branded versions go through rigorous safety testing that compounded products don’t. Ask your provider about manufacturer savings programs or copay assistance if access to a branded version is a concern.

Will gastroparesis from a GLP-1 go away if I stop taking it?

Many patients see GI symptoms improve after discontinuing the medication. But some cases of gastroparesis appear to be persistent even after stopping, based on reports in the ongoing MDL 3094 litigation (over 3,000 cases filed as of early 2026). If you develop severe nausea, vomiting, or stomach pain that doesn’t improve with dose adjustments, talk to your provider about stopping.